Impact Biomedical Inc. is a majority owned subsidiary of DSS, Inc. The company has technology assets for licensing and partnering, products for distribution and sales, and strategic investments in healthcare.
Impact Biomedical Inc. provides unique technology provider and business capabilities in addressing unmet needs in human healthcare and wellness.
(FDA/EMA Regulated)
Technologies / Products
Core Technologies
Summary: Impact Biomedical FDA / MedTech Pipeline U.S.
PH I
2029/2036
Small molecule x-bonded polyphenol compounds with potential application in neurological and inflammatory disorders.
Summary : Impact Biomedical OTC/Consumer U.S.
Combination of generally recognized as safe(GRAS) polyphenols with potential application as antiviral, supplements, or medication.
Marketing data/claims.
2036 Method and composition for treating influenza, Ebola, and rhinovirus
Sugar and inositol with potential to lower glycemic index, HbA1c, and beta cell protective effect as part of healthy diet.
Marketing data/claims. $2MM
Pending. Method and composition for unique combination of sugar and inositol which inhibits the inflammatory and metabolic response of sugar alone.
Combination of specialized botanical ingredients(e.g., terpenes) with potential application as insect repellent, anti-microbial, or as an additive in detergents, lotions, shampoo, fabrics and other substances
Marketing data/claims. $1MM
Allowed and awaiting issue as insect repellent. Pending. Antimicrobial applications.
Precision probiotics which optimizes probiotic formula with individual metabolism and need.
Marketing data/claims. $2MM
Pending. Precision match between individual and probiotics for allergy, gut, and mood.
Photo-catalytic oxidation(PCO) method of air purification which is designed to simulate natures natural process indoors to actively purify air and surfaces safely, supporting a healthy lifestyle.
Marketing data/claims. $TBDMM
TBD